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BACKGROUND: To appropriately manage uncontrolled
hypertension, clinicians must decide whether blood pres-
sure (BP) is above goal due to a need for additional med-
ication or to medication nonadherence. Yet, clinicians are
poor judges of adherence, and uncertainty about adher-
ence may promote inertia with respect to medication
modification.
OBJECTIVE: We aimed to determine the effect of sharing
electronically-measured adherence data with clinicians
on the management of uncontrolled hypertension.
DESIGN: This was a cluster randomized trial.
PARTICIPANTS: Twenty-four primary care providers (12
intervention, 12 usual care; cluster units) and 100
patients with uncontrolled hypertension (65 intervention,
35 usual care) were included in the study.
INTERVENTIONS: At one visit per patient, clinicians in
the intervention group received a report summarizing
electronically measured adherence to the BP regimen
and recommended clinical actions. Clinicians in the con-
trol group did not receive a report.
MAINMEASURES: The primary outcomewas the propor-
tion of visits with appropriate clinical management
(i.e., treatment intensification among adherent patients
and adherence counseling among nonadherent patients).
Secondary outcomes included patient-rated quality of
care and communication during the visit.
KEY RESULTS: The proportion of visits with appropriate
clinicalmanagement was higher in the intervention group
than the control group (45 out of 65; 69 %) versus (12 out
of 35; 34 %; p=0.001). A higher proportion of adherent
patients in the intervention group had their regimen in-
tensified (p=0.01), and a higher proportion of nonadher-
ent patients in the intervention group received adherence
counseling (p=0.005). Patients in the intervention group
were more likely to give their clinician high ratings on
quality of care (p=0.05), and on measures of patient-
centered (p=0.001) and collaborative communication
(p=0.02).
CONCLUSIONS: Providing clinicians with electronically-
measured antihypertensive adherence reports reduces
inertia in the management of uncontrolled hypertension.
TRIAL REGISTRATION: NCT01257347; http://clinical-
trials.gov/show/NCT01257347
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inertia; randomized clinical trial.
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INTRODUCTION
Hypertension is the most common chronic illness in devel-
oped countries, affecting approximately 30 % of U.S.
adults.1,2 Despite strong evidence that controlling hyperten-
sion improves cardiovascular outcomes and lowers health care
costs,3–5 one in three patients prescribed medications for hy-
pertension are not reaching guideline-recommended blood
pressure (BP) goals.6 Thus, improving BP control remains a
major unmet public health goal.7,8
Two major reasons for uncontrolled hypertension are
medication nonadherence9–11 and clinical inertia—defined
here as a lack of treatment intensification despite an ele-
vated BP.12–16 At least one-third of patients do not adhere
to their antihypertensive regimen.17,18 Accordingly,
experts recommend assessing medication adherence prior
to intensifying treatment.19–21 Yet clinicians are poor at
accurately identifying nonadherence and are often uncer-
tain about the true level of adherence.22,23 Uncertainty
may foster the Bwait until next visit^ approach that com-
monly underlies clinical inertia.13
Electronic monitoring is commonly regarded as the
best available measure of day-to-day medication adher-
ence.24,25 Electronic monitoring is less vulnerable to
recall bias and over-reporting than patient-reported ad-
herence measures.26 Electronic monitoring also provides
objective information on the extent of adherence imme-
diately prior to BP measurement, and hence has the
potential to maximally inform management decisions
for uncontrolled hypertension.27
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Accordingly, we designed a cluster randomized trial to deter-
mine whether providing clinicians with electronically measured
adherence data in conjunction with clinical decision support
could improve the management of uncontrolled hypertension.
The goal was to directly assess the impact of the receipt of such a
report on hypertension management during a single patient visit.
Clustering was performed at the clinician level to prevent spill-
over effects from exposure to the adherence feedback interven-
tion among clinicians in the control arm. By prompting in-
creased consideration of adherence in management decisions
and reducing uncertainty about adherence, we hypothesized that
providing clinicians with electronic adherence data would lead
to reduced clinical inertia. Secondary goals were to determine
the effect of the intervention on patient–clinician communication
and patient satisfaction with hypertension care.
METHODS
Design and Setting
The design was a two-arm, parallel-group, cluster randomized
clinical trial conducted at two hospital-based primary care
practices in New York City from 2010 to 2014. Both practices
serve racially and ethnically diverse patient populations from
underserved communities. Primary care providers comprised
the clusters.
Participants
Primary care providers were eligible if they had completed
clinical training and maintained a continuity practice at one of
the two sites. They also had to have at least one encounter with
an eligible patient.
Patients were eligible for a run-in if they had an established
diagnosis of hypertension; were prescribed at least one BP
medication; had at least two consecutive clinic visits with
elevated BP according to JNC-7 guidelines (i.e., BP≥140/90
mmHg or≥130/80 mmHg if diabetes or chronic kidney dis-
ease)28; were 18 to 80 years old; and had at least one prior visit
with a clinician enrolled in the study. Patients were excluded if
they had severe mental illness; resided in a long-term care
facility; were unable to use the electronic adherence device
due to physical or cognitive impairment; were non-English or
non-Spanish speaking; or were unavailable for follow-up.
Research assistants confirmed initial eligibility by measuring
BP using a standard protocol recommended by the American
Heart Association and a BP Tru automatic sphygmomanome-
ter (BP Tru Medical Devices; Coquitlam, Canada).29 Final
patient eligibility was assessed at the next scheduled clinic
visit. Patients were eligible if they continued to have elevated
BP at this visit. Patients were excluded if electronic adherence
data were unavailable at the visit. Institutional Review Boards
of the Icahn School of Medicine at Mount Sinai and Columbia
University Medical Center approved the protocol. All clini-
cians and patients provided informed consent.
Baseline Assessments
At enrollment, clinicians completed a questionnaire that
assessed demographic characteristics and years in practice.
At enrollment, patients completed an interview assessing de-
mographic characteristics. Medical problems and medications
were abstracted from the electronic medical record. Charlson
score was computed based on patients’medical problem list.30
Medication Adherence
Medication adherence was assessed using the four-
compartmentMedSignals® pillbox (VitalSignals Inc., Lexing-
ton, KY). The device records the date and time when each
compartment is opened. Adherence data are transmitted from
the pillbox to the MedSignals server via landline or, for
devices used in the final year of the study, via a cell phone in
the device. Patients were instructed to fill the pillbox with their
antihypertensive medications. The device’s reminder system
was disabled. Adherence to each BP medication was calculat-
ed as the percent of doses taken as prescribed. Extra doses
were excluded from adherence calculations. Days on which
patients were hospitalized or had been instructed by their
clinician to stop taking a monitored medication were also
excluded. Overall regimen adherence was calculated as the
mean adherence to all monitored BP medications. As per
convention and expert opinion, patients were categorized as
nonadherent if adherence was less than 80 %.26
Randomization and Allocation Concealment
Providers were block randomized in a 1:1 ratio to the inter-
vention or control group. Randomization was generated by a
computerized random number sequence. Provider assign-
ments were known only to a third party who had no role in
outcome assessments. Randomization was stratified by re-
cruitment site. Patients were analyzed in the group to which
their provider was randomized. To assess blinding, research
assistants guessed which group patients had been assigned to
after completing outcome assessments.
Intervention
The intervention occurred at the clinician cluster level. At the
time of clinician enrollment, clinicians in the intervention
group received a brief, one-time training (< 10 minutes) in
how to interpret the adherence report. Subsequently, these
clinicians were provided with a one-time adherence report
immediately prior to a visit with eligible patients. The one-
page report (Appendix Figure 1) displayed the percent adher-
ence to each BP medication and to the overall regimen for the
entire monitoring period and the 7 days preceding the inter-
vention visit. The report also provided clinical decision sup-
port by listing Bsuggested clinical actions^ according to ad-
herence status. However, the actions taken were at clinicians’
discretion. Patients assigned to the intervention group were
informed their adherence was recorded by the electronic
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pillbox and might be shared with their clinician depending on
randomization, but did not receive adherence counseling by
study personnel.
Usual Care
Clinicians randomized to the control group did not receive an
adherence report and were expected to manage their patients
according to usual care. Like patients in the intervention
group, patients in the control group were informed their ad-
herence was recorded and might be shared with their clinician
depending on randomization. No adherence counseling was
provided. As neither providers nor patients in the control
group had access to adherence data, the potential for contam-
ination was reduced.
Outcomes
The primary outcome was appropriateness of management of
uncontrolled hypertension at visits with adherence report feed-
back versus usual care. Appropriateness depended on adher-
ence status. In adherent patients (regimen adherence during the
7 days prior to intervention visit ≥ 80 %), management was
categorized as appropriate if providers intensified the regimen,
ordered testing for identifiable causes of hypertension, or re-
ferred patients to a hypertension specialist. In nonadherent
patients (regimen adherence during entire monitoring period <
80%), management was categorized as appropriate if providers
conducted adherence counseling or simplified the regimen to
facilitate adherence. Adherence counseling was defined as any
documentation of assessing, arranging, assisting, or advising
patients about adherence to their BP medications. For patients
who were nonadherent over the entire monitoring period but
adherent in the week prior to the intervention visit, management
was defined as appropriate if providers conducted adherence
counseling and took action to intensify treatment. Two medi-
cally trained study personnel blinded to group assignment
independently abstracted data pertaining to outcome assess-
ments from medical records after a third person had reviewed
records to redact wording that could reveal group assignment.
Differences in categorization were resolved through consensus.
Secondary outcomes included patient ratings of the quality
of care during the visit (Bpoor,^ Bfair,^ Bgood,^ Bvery good,^
Bexcellent^); satisfaction with the amount of time spent during
the visit (Btoo little,^ Btoo much,^ Bjust right^); and percep-
tions of patient-centered and collaborative communication.
Collaborative communication was assessed using a four-item
questionnaire adapted from the Patient Assessment of Chronic
Illness scale.31,32 Patient-centered communication was
assessed by adapting a four-item questionnaire assessing com-
munication around antidepressants.33 For both questionnaires,
response options for individual items ranged from 0 (Bnot at
all^) to 3 (Bvery much^), and items were summed such that
scores ≥ 8 indicated collaborative or patient-centered commu-
nication, respectively. Patient-rated outcomes were assessed
by interviewing patients immediately after clinician visits.
Process Evaluation
Patients were asked about the ease of using the electronic
pillbox using a five-item Likert scale (Bvery hard^ to Bvery
easy^). They were also asked whether they would bewilling to
use the pillbox again if asked by their clinicians.
Statistical Analysis
The kappa statistic was used to assess agreement between
outcome assessors’ guesses about group assignment. General-
ized estimating equation (GEE) models (logit link) fitted with
clinician as the cluster variable, appropriateness of hyperten-
sion management as the outcome, and intervention group as
the explanatory variable were used to assess the effect of the
intervention on outcomes. Post-hoc sensitivity analyses were
conducted in which the sample was restricted to patients who
met JNC-8 criteria for uncontrolled hypertension (BP≥140/90
mmHg irrespective of diabetes or chronic kidney disease
status),34 as these guidelines were released during the final
year of recruitment. A GEE model was also used to estimate
the intraclass correlation coefficient (ICC) for appropriateness
of management at the clinician level.
Sample Size
Sample size was calculated to have sufficient power to detect
meaningful differences in appropriateness of hypertension
management between intervention and control groups. Each
patient–clinician encounter was treated as independent and the
sample size was inflated to account for the design effect (DE)
of clustering of patients within clinician where DE=1+ (num-
ber of patients per cluster – 1)*intra-class correlation coeffi-
cient (ICC).35,36 Average cluster size was estimated at seven
patients per provider. We estimated a small ICC (0.01).35–38
The sample size calculation was performed with a significance
level of 0.05 and 80 % power. Based on prior studies showing
clinical inertia in 60 % of hypertension visits,35–41 we estimat-
ed needing a sample of 200 patient–clinician visits to detect a
33% improvement in visits with appropriate management.We
included a stopping rule in which recruitment would be
stopped at the midpoint for futility if the z-score was negative
or for efficacy if the z-score was positive and the p val-
ue≤0.001.42,43 As we met the efficacy stopping rule, enroll-
ment stopped after 100 patients. All patient–clinician encoun-
ters were analyzed according to the group they were randomly
assigned. SPSS (version 22.0, IBM Corp., Armonk, NY) was
used for all analyses.
RESULTS
Participant Characteristics
We enrolled 49 primary care providers. No providers declined
participation. Twenty-four providers (12 intervention, 12 con-
trol) had at least one visit at which the adherence report was
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available (Fig. 1). Characteristics of providers in the interven-
tion and control groups were similar. (Table 1).
We screened 497 patients, and consented 200 for the run-in.
Forty-three patients (9 %) declined participation at the screen-
ing visit and 254 patients (51 %) were ineligible, primarily due
to controlled BP (n=92), unavailability for follow-up (n=27),
severe mental illness (n= 17), and cognitive impairment
(n=16). Of the 200 patients who consented to the electronic
monitoring run-in, 100 had adherence reports available at the
follow-up visit and were eligible for the trial. Reasons for
ineligibility after the run-in included controlled BP (n=37),
no pillbox data (n=24), adherence report not provided to
clinician on time (n=15); other reasons (n= 9); declined
follow-up (n= 9); lost to follow-up (n= 5); and deceased
(n=1).
Due to chance, alone, 65 patients belonged to providers in
the intervention group and 35 to providers in the control
group. Characteristics of patients in each group were similar
(Table 2). Patients were representative of their clinic popula-
tions with mean age of 64 years, 72 %women, 75%Hispanic,
54 % having a less than high school education, and 83 %
havingMedicaid or self-pay health insurance status. The mean
BP at the time of the intervention was 155/83 mmHg, and
56 % of patients were prescribed ≥ 3 BP medications. Medi-
cation adherence was measured for a mean of 52±32 days.
Forty-one percent of patients were nonadherent (<80 % of
prescribed doses); three of these patients were adherent in the
week before the intervention visit. The majority of patients
(64 %) found the electronic pillbox Bvery easy^ to use, and
almost all (94 %) said they would use it again if asked.
Outcomes
A greater proportion of patients assigned to the intervention
group received appropriate management of uncontrolled hy-
pertension than patients assigned to the control group (69 %
versus 34%; p=0.001; Table 3). A sensitivity analysis restrict-
ing the sample to patients with BP ≥140/90 mmHg (N=87)
showed similar results (70 % of intervention patients versus
40 % of control patients; p=0.007). The ICC for appropriate-
ness of management was 0.06. Outcome assessors’ guessed
group assignment correctly 56 % of the time (kappa 0.02,
p=0.72).
A greater proportion of adherent patients had their BP
regimen intensified if they were in the intervention group
compared to the control group (56 % versus 26 %;
p=0.01). There were no differences in the proportions of
adherent patients that were ordered tests for identifiable
hypertension or were referred to hypertension specialists.
A greater proportion of nonadherent patients received
adherence counseling if they were in the intervention
group compared to the control group (84 % versus
39 %, p=0.005). There was no difference in the propor-
tion of nonadherent patients that had their BP regimen
simplified.
Patients assigned to the intervention were more likely to
give their providers high ratings on quality of care during the
visit (p=0.05), patient-centered (p=0.001), and collaborative
communication about hypertension (p=0.02) (Table 4). There
was also a trend toward intervention patients being more likely
to rate the amount of time spent during the visit as Bjust right^
(92 % versus 80 %, p=0.11).
Figure 1. CONSORT (Consolidated Standards of Reporting Trials) extension for cluster randomized trials flow diagram of the measuring
adherence to control hypertension (MATCH) Trial*.
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CONCLUSIONS
We found that providing electronically measured adherence
data plus clinical decision support to clinicians at the time of
primary care visits substantially improved clinician manage-
ment of uncontrolled hypertension. The receipt of adherence
reports increased regimen intensification in adherent patients
and increased medication adherence counseling in nonadher-
ent patients. Sharing objectively measured adherence data also
improved patient ratings of quality of care and clinician com-
munication. These results provide evidence in support of a
measurement-guided medication management approach to
treating patients with uncontrolled hypertension.27
These results were consistent with several small studies
assessing the impact of sharing objective measures of BP
medication adherence with providers.44–46 In the study by
Burnier et al., electronically monitoring patients with resistant
hypertension was associated with reduced clinical inertia and
improved BP control. This study, however, was limited by its
small sample size (N=41) and lack of control group. The
study by Hyman et al. tested an intervention to reduce uncer-
tainty about reasons for uncontrolled BP, and showed that their
intervention reduced clinical inertia. Yet, in this study, elec-
tronic monitoring was optional and but one-part of a multi-
Table 1. Clinician Characteristics According to Group Assignment








Age in years, mean
(SD)
46 (11) 48 (10)
Female 7 (58) 6 (50)
Hispanic 1 (9) 3 (25)
White 9 (75) 10 (83)
Years in practice,
mean (SD)
15 (12) 17 (11)
Data are presented as N (%) unless otherwise specified
Table 2. Patient Characteristics According to Group Assignment in
the Measuring Adherence to Control Hypertension (MATCH) Trial





Age in years, mean (SD) 64 (9) 64 (8)
Female 50 (77) 22 (63)
Hispanic 47 (72) 28 (80)
Born outside United States* 46 (71) 29 (83)
Non-White 42 (71) 24 (75)
Less than high school
education
35 (55) 17 (49)
Medicaid or self-pay 55 (85) 28 (80)
Lives alone 53 (82) 25 (71)
Years with provider, median
(IQR)
4 (7) 5 (13)
Diabetes 37 (57) 26 (74)
Chronic kidney disease
(GFR< 60)
20 (31) 10 (29)
Charlson Comorbidity
Index, mean (SD)




5.4 (2.5) 4.9 (2.1)
Systolic BP, mean (SD), mm
Hg
156 (17) 154 (16)
Diastolic BP, mean (SD),
mm Hg
83 (13) 83 (13)
Prescribed 3 or more BP
medications
34 (52) 22 (63)
Nonadherent (< 80 %) to BP
regimen
27 (42) 14 (40)
Data are presented as N (%) unless otherwise specified. Data are
missing from two or fewer participants for all measures except Charlson
for which data are missing on nine participants
* Patients born in Puerto Rico were categorized as born outside the
United States
IQR interquartile range; PHQ 8-item Patient Health Questionnaire; BP
blood pressure
Table 3. Comparison of Clinician Management According to Study











in week prior to outcome
visit, only
N= 34 N= 19
Intensified regimen 19 (56) 5 (26) 0.01
Ordered identifiable
hypertension tests






19 (56) 6 (32) 0.02
Among patients
nonadherent over entire
monitoring period or in
week prior to outcome
visit
N= 32 N= 18
Documented addressing
adherence
27 (84) 7 (39) 0.005
Changed regimen to
improve adherence
3 (9) 1 (6) 0.65
Overall appropriate
management
27 (84) 7 (39) 0.005
Among all patients N= 65 N= 35
Overall appropriate
management
45 (69) 12 (34) 0.001
Data are presented as N (%) unless otherwise specified
The overall number of patients who received appropriate clinical action
does not add up to the sum of the individual actions, as patients could
have received more than one appropriate clinical actions
Table 4. Comparison of Patient-Rated Quality of Care and
Clinician Communication According to Study Arm in the Measur-

















32 (49) 10 (29) 0.02
Quality of care during
visit rated very good or
excellent (versus poor,
fair, or good)
45 (71) 18 (53) 0.05
Just the right amount of
time for visit
60 (92) 28 (80) 0.11
Data are presented as N (%) unless otherwise specified. Data are
missing from 3 participants for quality of care rating
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component intervention. Our study, in contrast, demonstrated
that electronic monitoring feedback, alone, reduced clinical
inertia. The trial by Santschi et al. most closely resembled our
design in that they utilized a cluster randomized design to
demonstrate that electronically monitoring adherence to a
single BP medication was associated with increased medica-
tion titrations and better BP control. In this small trial (N=65),
however, their intervention was done in collaboration with
pharmacists and appropriateness of clinical actions was not
evaluated. We extended their findings by demonstrating that
providing clinicians, alone, with an electronic adherence re-
port not only reduced clinical inertia, but improved the appro-
priateness of clinical actions and patient–clinician
communication.
There were several strengths of this study. First, few studies
have sought to maximally reduce uncertainty about adherence
by electronically measuring adherence to the near-complete
antihypertensive regimen as opposed to a single medication.
Second, the study was conducted in a socioeconomically
vulnerable patient population with a large number of racial
and ethnic minorities—a population often excluded from clin-
ical trials.
The study also had several limitations. A substantial num-
ber of patients who underwent electronic monitoring were not
included in the analyses due to non-compliance with electron-
ic monitoring and lack of timely reports, and thus, the results
likely represent an optimistic estimate of the effect of elec-
tronic monitoring in clinical inertia in practice. Electronic
monitoring cannot confirm whether pillbox openings repre-
sent pill-taking behavior. Clinicians in the control group did
not receive a report, and hence, one cannot determine the
extent to which the intervention effect was due to a nonspecific
prompt about adherence or to the receipt of the electronic
adherence report. The intervention was only evaluated at a
single patient visit; whether continuous electronic monitoring
is needed to have a sustained impact on clinical inertia is
worthy of further study. The trial was stopped early, and thus,
even with the presence of a stopping rule, effect sizes should
be interpreted cautiously. There were an unequal number of
patients in the intervention and control groups, but this was
attributable to the lack of balanced randomization at the patient
level. The measure of adherence counseling has not been
externally validated. A majority of patients had uncontrolled
BP despite three or more BP medications, and patients were
only eligible if they had persistently elevated BP even after
adherence monitoring. Thus, the generalizability of our find-
ings to other patient populations is unknown. The trial was not
powered to detect differences in BP; a much larger number of
patients is needed to test this outcome. Finally, electronic
monitoring is not yet widely accessible in routine practice.
Nevertheless, the advent of wireless adherence devices whose
data can autopopulate electronic medical records may increase
the feasibility of this approach in the future.
In summary, providing clinicians with electronic adherence
data at the time of patient visits was an efficacious approach to
increasing regimen intensification in adherent patients and
increasing adherence counseling in nonadherent patients. Fu-
ture studies should assess the impact of such an intervention
on medication adherence and BP. Efforts to integrate electron-
ic monitoring into clinical settings hold promise for improving
patient-centered care and hypertension control in patients with
uncontrolled hypertension.
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